Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,735 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: work therapy Clear all

Conditions: Fractures, Bone
Interventions: CPM; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Unresectable Melanoma
Interventions: Nivolumab, Duvelisib; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: CTx001; Genetic
Lead sponsor: Complement Therapeutics; Industry
Eligibility: 55 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more

Conditions: Unresectable Hepatocellular Carcinoma
Interventions: Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab,; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Buffalo, New York + 2 more

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Oral contraceptive, Acetaminophen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Sickle Cell Disease
Interventions: Cogmed+; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 7 Years to 16 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Burnout, Work Engagement, Psychological Resilience, Work-Related Stress
Interventions: Augmented Mindfulness-based Intervention, Mindfulness-based intervention; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Obesity
Interventions: Positive end-expiratory pressure (PEEP), ZEEP; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Heart rate variability biofeedback, Placebo; Behavioral
Lead sponsor: Fred Wamboldt, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 2
States / cities: Denver, Colorado • Piscataway, New Jersey

Conditions: Dry Eye Disease
Interventions: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Surface Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Azusa, California • Hemet, California + 33 more

Conditions: Healthy Participants
Interventions: Swedish Massage Therapy, Light Touch Control; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Influenza, Human
Interventions: Flu shot text messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 734,383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Peripheral T-Cell Lymphoma
Interventions: Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteer
Interventions: BIIB122; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Alzheimer's Disease
Interventions: Home based occupational therapy, Best practices primary care; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 45 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Anxiety Disorders, Depression, Obsessive-Compulsive Disorder, Adolescent - Emotional Problem, Emotional Disorder
Interventions: Unified Protocol for Emotional Disorders in Adolescents (UP-A); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 13 Years to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Diabetes, Coronary Artery Disease
Interventions: Strict Glycemic Control for one year post-op CABG; Drug
Lead sponsor: Providence Heart & Vascular Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Obesity, Overweight, Severe Mental Disorder
Interventions: iOTA text messaging intervention, Health Education text messaging intervention; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Miami, Florida • St Louis, Missouri

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Opioid-use Disorder
Interventions: reSET-O app; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Harrisburg, Pennsylvania

Conditions: Retroperitoneal Sarcoma
Interventions: Not listed
Lead sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 6
States / cities: Los Angeles, California • Jacksonville, Florida • Tampa, Florida + 3 more

Conditions: Critical Illness, Communication Disabilities
Interventions: EMPOWER, Enhanced Usual Care; Behavioral · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Flushing, New York • New York, New York

Conditions: Opioid Use Disorder
Interventions: SUN, SUN + Telebridge, ED-ITT, ED-ITT + BHS; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Colton, California

Conditions: Physician Well-being, Cognitive Function, Diet Modification, Diet Habit, Shift-Work Related Sleep Disturbance, Sleep Deprivation
Interventions: Dietary Modification; Other
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Continuous Passive Motion Following Fixation of Pelvic and Knee Fractures

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

Buckeye Pause Bundle

Effects of Different PEEP Levels on Work of Breathing in Morbidly Obese Patients Prior to and After Extubation

Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

Massage: Neuroimaging and Correlates of Response - 1-week Study

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Alzheimer's Disease Multiple Intervention Trial

Unified Protocol for Adolescents (UP-A) Change Processes

United States Coronary Artery Bypass Surgery (CABG) Diabetes Project (USCDP) Pilot Study

Interactive Obesity Treatment Approach for Obesity Prevention in Adults With Early Serious Mental Illness: iOTA-SMI

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

reSET-O RCT (Randomized Controlled Trial)

REtroperitoneal SArcoma Registry: an International Prospective Initiative

Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience Among Surrogate Decision-Makers of ICU Patients

Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder

Performance Nutrition for Residents and Fellows